The bond offering was met with enthusiastic response from high-quality investors, with a total final combined order book above EUR 3.1bn (2.6 times oversubscribed). The combined allocations came from investors from different geographies, highlighting the global appeal of Roquette.
The net proceeds from the bond offering will mainly be used to refinance the announced acquisition of IFF Pharma Solutions, expected to close in the first half of 2025.(1)
Pierre Courduroux, CEO of Roquette declared: “We are extremely proud of the success of this inaugural bond issuance, which marks a significant milestone in our long history of value creation for all our stakeholders. The strong demand from investors reflects their confidence in our strategy and our ability to continue innovating and expanding into high-growth markets. Once we complete the acquisition of IFF Pharma Solutions, we will not only expand our capabilities in the pharmaceutical excipients sector but also transform Roquette into a company with a more balanced Health and Nutrition offering and an expanded global presence."
Following the success of the inaugural bond offering, the future acquisition of IFF Pharma Solutions will complement Roquette’s existing expertise. This will allow the company to expand its reach in key markets and deliver a broader range of innovative, high-value products to its clients, particularly in the fast-growing pharmaceutical excipients sector. Roquette will also strengthen its R&D capabilities and continue staying ahead of the curve to help improve, sustain and save lives.
As Roquette tapped the bond market for the first time, it remains a family-owned, independent company. Its long-standing commitment to innovation, sustainable growth, and strategic consistency has helped build a robust financial profile as a compelling bond issuer. By entering the public and regulated credit markets, Roquette is expanding and reinforcing its financing strategy to continue investing in new growth opportunities and delivering value to all stakeholders.
1. Roquette Takes Decisive Strategic Step and Signs Agreement to Acquire IFF Pharma Solutions
To learn more about Roquette, please visit this page.
Press contacts
- Brunswick: Aurélia de Lapeyrouse, +33 (0) 6 21 06 40 33, [email protected]
- Roquette Corporate Communications: Susannah Duquesne, +33 (0) 6 64 42 40 98, [email protected]
- Roquette Financial Communications: Eloïse de la Chaux, [email protected], +33 (0) 7 60 11 04 09